Clinical Trial Update: Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) [Phase 2]

View source ↗

Summary

Phase 2 extension study of NS-065/NCNP-01 in boys with Duchenne muscular dystrophy completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• NS-065/NCNP-01

Snippet

Sponsor: NS Pharma, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2022-11-18